MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD

Major-Monfried, H., Renteria, A. S., Pawarode, A., Reddy, P., Ayuk, F., Holler, E., Efebera, Y. A., Hogan, W. J., Wölfl, M., Qayed, M., Hexner, E. O., Wudhikarn, K., Ordemann, R., Young, R., Shah, J., Hartwell, M. J., Chaudhry, M. S., Aziz, M., Etra, A., Yanik, G. A., Kröger, N., Weber, D., Chen, Y.-B., Nakamura, R., Rösler, W., Kitko, C. L., Harris, A. C., Pulsipher, M., Reshef, R., Kowalyk, S., Morales, G., Torres, I., Özbek, U., Ferrara, J. L. M., Levine, J. E.
American Society of Hematology (ASH)
Published 2018

Publication Date:	2018-06-22
Publisher:	American Society of Hematology (ASH)
Print ISSN:	0006-4971
Electronic ISSN:	1528-0020
Topics:	Biology Medicine
Keywords:	Transplantation, Free Research Articles, CME article, Clinical Trials and Observations
Published by:	http://www.hematology.org/

Staff View

_version_	1836398981243994112
autor	Major-Monfried, H., Renteria, A. S., Pawarode, A., Reddy, P., Ayuk, F., Holler, E., Efebera, Y. A., Hogan, W. J., Wölfl, M., Qayed, M., Hexner, E. O., Wudhikarn, K., Ordemann, R., Young, R., Shah, J., Hartwell, M. J., Chaudhry, M. S., Aziz, M., Etra, A., Yanik, G. A., Kröger, N., Weber, D., Chen, Y.-B., Nakamura, R., Rösler, W., Kitko, C. L., Harris, A. C., Pulsipher, M., Reshef, R., Kowalyk, S., Morales, G., Torres, I., Özbek, U., Ferrara, J. L. M., Levine, J. E.
beschreibung	Acute graft-versus-host disease (GVHD) is treated with systemic corticosteroid immunosuppression. Clinical response after 1 week of therapy often guides further treatment decisions, but long-term outcomes vary widely among centers, and more accurate predictive tests are urgently needed. We analyzed clinical data and blood samples taken 1 week after systemic treatment of GVHD from 507 patients from 17 centers of the Mount Sinai Acute GVHD International Consortium (MAGIC), dividing them into a test cohort (n = 236) and 2 validation cohorts separated in time (n = 142 and n = 129). Initial response to systemic steroids correlated with response at 4 weeks, 1-year nonrelapse mortality (NRM), and overall survival (OS). A previously validated algorithm of 2 MAGIC biomarkers (ST2 and REG3α) consistently separated steroid-resistant patients into 2 groups with dramatically different NRM and OS ( P 〈 .001 for all 3 cohorts). High biomarker probability, resistance to steroids, and GVHD severity (Minnesota risk) were all significant predictors of NRM in multivariate analysis. A direct comparison of receiver operating characteristic curves showed that the area under the curve for biomarker probability (0.82) was significantly greater than that for steroid response (0.68, P = .004) and for Minnesota risk (0.72, P = .005). In conclusion, MAGIC biomarker probabilities generated after 1 week of systemic treatment of GVHD predict long-term outcomes in steroid-resistant GVHD better than clinical criteria and should prove useful in developing better treatment strategies.
citation_standardnr	6289603
datenlieferant	ipn_articles
feed_id	310
feed_publisher	American Society of Hematology (ASH)
feed_publisher_url	http://www.hematology.org/
insertion_date	2018-06-22
journaleissn	1528-0020
journalissn	0006-4971
publikationsjahr_anzeige	2018
publikationsjahr_facette	2018
publikationsjahr_intervall	7984:2015-2019
publikationsjahr_sort	2018
publisher	American Society of Hematology (ASH)
quelle	Blood
relation	http://www.bloodjournal.org/cgi/content/short/131/25/2846?rss=1
schlagwort	Transplantation, Free Research Articles, CME article, Clinical Trials and Observations
search_space	articles
shingle_author_1	Major-Monfried, H., Renteria, A. S., Pawarode, A., Reddy, P., Ayuk, F., Holler, E., Efebera, Y. A., Hogan, W. J., Wölfl, M., Qayed, M., Hexner, E. O., Wudhikarn, K., Ordemann, R., Young, R., Shah, J., Hartwell, M. J., Chaudhry, M. S., Aziz, M., Etra, A., Yanik, G. A., Kröger, N., Weber, D., Chen, Y.-B., Nakamura, R., Rösler, W., Kitko, C. L., Harris, A. C., Pulsipher, M., Reshef, R., Kowalyk, S., Morales, G., Torres, I., Özbek, U., Ferrara, J. L. M., Levine, J. E.
shingle_author_2	Major-Monfried, H., Renteria, A. S., Pawarode, A., Reddy, P., Ayuk, F., Holler, E., Efebera, Y. A., Hogan, W. J., Wölfl, M., Qayed, M., Hexner, E. O., Wudhikarn, K., Ordemann, R., Young, R., Shah, J., Hartwell, M. J., Chaudhry, M. S., Aziz, M., Etra, A., Yanik, G. A., Kröger, N., Weber, D., Chen, Y.-B., Nakamura, R., Rösler, W., Kitko, C. L., Harris, A. C., Pulsipher, M., Reshef, R., Kowalyk, S., Morales, G., Torres, I., Özbek, U., Ferrara, J. L. M., Levine, J. E.
shingle_author_3	Major-Monfried, H., Renteria, A. S., Pawarode, A., Reddy, P., Ayuk, F., Holler, E., Efebera, Y. A., Hogan, W. J., Wölfl, M., Qayed, M., Hexner, E. O., Wudhikarn, K., Ordemann, R., Young, R., Shah, J., Hartwell, M. J., Chaudhry, M. S., Aziz, M., Etra, A., Yanik, G. A., Kröger, N., Weber, D., Chen, Y.-B., Nakamura, R., Rösler, W., Kitko, C. L., Harris, A. C., Pulsipher, M., Reshef, R., Kowalyk, S., Morales, G., Torres, I., Özbek, U., Ferrara, J. L. M., Levine, J. E.
shingle_author_4	Major-Monfried, H., Renteria, A. S., Pawarode, A., Reddy, P., Ayuk, F., Holler, E., Efebera, Y. A., Hogan, W. J., Wölfl, M., Qayed, M., Hexner, E. O., Wudhikarn, K., Ordemann, R., Young, R., Shah, J., Hartwell, M. J., Chaudhry, M. S., Aziz, M., Etra, A., Yanik, G. A., Kröger, N., Weber, D., Chen, Y.-B., Nakamura, R., Rösler, W., Kitko, C. L., Harris, A. C., Pulsipher, M., Reshef, R., Kowalyk, S., Morales, G., Torres, I., Özbek, U., Ferrara, J. L. M., Levine, J. E.
shingle_catch_all_1	MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD Transplantation, Free Research Articles, CME article, Clinical Trials and Observations Acute graft-versus-host disease (GVHD) is treated with systemic corticosteroid immunosuppression. Clinical response after 1 week of therapy often guides further treatment decisions, but long-term outcomes vary widely among centers, and more accurate predictive tests are urgently needed. We analyzed clinical data and blood samples taken 1 week after systemic treatment of GVHD from 507 patients from 17 centers of the Mount Sinai Acute GVHD International Consortium (MAGIC), dividing them into a test cohort (n = 236) and 2 validation cohorts separated in time (n = 142 and n = 129). Initial response to systemic steroids correlated with response at 4 weeks, 1-year nonrelapse mortality (NRM), and overall survival (OS). A previously validated algorithm of 2 MAGIC biomarkers (ST2 and REG3α) consistently separated steroid-resistant patients into 2 groups with dramatically different NRM and OS ( P < .001 for all 3 cohorts). High biomarker probability, resistance to steroids, and GVHD severity (Minnesota risk) were all significant predictors of NRM in multivariate analysis. A direct comparison of receiver operating characteristic curves showed that the area under the curve for biomarker probability (0.82) was significantly greater than that for steroid response (0.68, P = .004) and for Minnesota risk (0.72, P = .005). In conclusion, MAGIC biomarker probabilities generated after 1 week of systemic treatment of GVHD predict long-term outcomes in steroid-resistant GVHD better than clinical criteria and should prove useful in developing better treatment strategies. Major-Monfried, H., Renteria, A. S., Pawarode, A., Reddy, P., Ayuk, F., Holler, E., Efebera, Y. A., Hogan, W. J., Wölfl, M., Qayed, M., Hexner, E. O., Wudhikarn, K., Ordemann, R., Young, R., Shah, J., Hartwell, M. J., Chaudhry, M. S., Aziz, M., Etra, A., Yanik, G. A., Kröger, N., Weber, D., Chen, Y.-B., Nakamura, R., Rösler, W., Kitko, C. L., Harris, A. C., Pulsipher, M., Reshef, R., Kowalyk, S., Morales, G., Torres, I., Özbek, U., Ferrara, J. L. M., Levine, J. E. American Society of Hematology (ASH) 0006-4971 00064971 1528-0020 15280020
shingle_catch_all_2	MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD Transplantation, Free Research Articles, CME article, Clinical Trials and Observations Acute graft-versus-host disease (GVHD) is treated with systemic corticosteroid immunosuppression. Clinical response after 1 week of therapy often guides further treatment decisions, but long-term outcomes vary widely among centers, and more accurate predictive tests are urgently needed. We analyzed clinical data and blood samples taken 1 week after systemic treatment of GVHD from 507 patients from 17 centers of the Mount Sinai Acute GVHD International Consortium (MAGIC), dividing them into a test cohort (n = 236) and 2 validation cohorts separated in time (n = 142 and n = 129). Initial response to systemic steroids correlated with response at 4 weeks, 1-year nonrelapse mortality (NRM), and overall survival (OS). A previously validated algorithm of 2 MAGIC biomarkers (ST2 and REG3α) consistently separated steroid-resistant patients into 2 groups with dramatically different NRM and OS ( P < .001 for all 3 cohorts). High biomarker probability, resistance to steroids, and GVHD severity (Minnesota risk) were all significant predictors of NRM in multivariate analysis. A direct comparison of receiver operating characteristic curves showed that the area under the curve for biomarker probability (0.82) was significantly greater than that for steroid response (0.68, P = .004) and for Minnesota risk (0.72, P = .005). In conclusion, MAGIC biomarker probabilities generated after 1 week of systemic treatment of GVHD predict long-term outcomes in steroid-resistant GVHD better than clinical criteria and should prove useful in developing better treatment strategies. Major-Monfried, H., Renteria, A. S., Pawarode, A., Reddy, P., Ayuk, F., Holler, E., Efebera, Y. A., Hogan, W. J., Wölfl, M., Qayed, M., Hexner, E. O., Wudhikarn, K., Ordemann, R., Young, R., Shah, J., Hartwell, M. J., Chaudhry, M. S., Aziz, M., Etra, A., Yanik, G. A., Kröger, N., Weber, D., Chen, Y.-B., Nakamura, R., Rösler, W., Kitko, C. L., Harris, A. C., Pulsipher, M., Reshef, R., Kowalyk, S., Morales, G., Torres, I., Özbek, U., Ferrara, J. L. M., Levine, J. E. American Society of Hematology (ASH) 0006-4971 00064971 1528-0020 15280020
shingle_catch_all_3	MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD Transplantation, Free Research Articles, CME article, Clinical Trials and Observations Acute graft-versus-host disease (GVHD) is treated with systemic corticosteroid immunosuppression. Clinical response after 1 week of therapy often guides further treatment decisions, but long-term outcomes vary widely among centers, and more accurate predictive tests are urgently needed. We analyzed clinical data and blood samples taken 1 week after systemic treatment of GVHD from 507 patients from 17 centers of the Mount Sinai Acute GVHD International Consortium (MAGIC), dividing them into a test cohort (n = 236) and 2 validation cohorts separated in time (n = 142 and n = 129). Initial response to systemic steroids correlated with response at 4 weeks, 1-year nonrelapse mortality (NRM), and overall survival (OS). A previously validated algorithm of 2 MAGIC biomarkers (ST2 and REG3α) consistently separated steroid-resistant patients into 2 groups with dramatically different NRM and OS ( P < .001 for all 3 cohorts). High biomarker probability, resistance to steroids, and GVHD severity (Minnesota risk) were all significant predictors of NRM in multivariate analysis. A direct comparison of receiver operating characteristic curves showed that the area under the curve for biomarker probability (0.82) was significantly greater than that for steroid response (0.68, P = .004) and for Minnesota risk (0.72, P = .005). In conclusion, MAGIC biomarker probabilities generated after 1 week of systemic treatment of GVHD predict long-term outcomes in steroid-resistant GVHD better than clinical criteria and should prove useful in developing better treatment strategies. Major-Monfried, H., Renteria, A. S., Pawarode, A., Reddy, P., Ayuk, F., Holler, E., Efebera, Y. A., Hogan, W. J., Wölfl, M., Qayed, M., Hexner, E. O., Wudhikarn, K., Ordemann, R., Young, R., Shah, J., Hartwell, M. J., Chaudhry, M. S., Aziz, M., Etra, A., Yanik, G. A., Kröger, N., Weber, D., Chen, Y.-B., Nakamura, R., Rösler, W., Kitko, C. L., Harris, A. C., Pulsipher, M., Reshef, R., Kowalyk, S., Morales, G., Torres, I., Özbek, U., Ferrara, J. L. M., Levine, J. E. American Society of Hematology (ASH) 0006-4971 00064971 1528-0020 15280020
shingle_catch_all_4	MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD Transplantation, Free Research Articles, CME article, Clinical Trials and Observations Acute graft-versus-host disease (GVHD) is treated with systemic corticosteroid immunosuppression. Clinical response after 1 week of therapy often guides further treatment decisions, but long-term outcomes vary widely among centers, and more accurate predictive tests are urgently needed. We analyzed clinical data and blood samples taken 1 week after systemic treatment of GVHD from 507 patients from 17 centers of the Mount Sinai Acute GVHD International Consortium (MAGIC), dividing them into a test cohort (n = 236) and 2 validation cohorts separated in time (n = 142 and n = 129). Initial response to systemic steroids correlated with response at 4 weeks, 1-year nonrelapse mortality (NRM), and overall survival (OS). A previously validated algorithm of 2 MAGIC biomarkers (ST2 and REG3α) consistently separated steroid-resistant patients into 2 groups with dramatically different NRM and OS ( P < .001 for all 3 cohorts). High biomarker probability, resistance to steroids, and GVHD severity (Minnesota risk) were all significant predictors of NRM in multivariate analysis. A direct comparison of receiver operating characteristic curves showed that the area under the curve for biomarker probability (0.82) was significantly greater than that for steroid response (0.68, P = .004) and for Minnesota risk (0.72, P = .005). In conclusion, MAGIC biomarker probabilities generated after 1 week of systemic treatment of GVHD predict long-term outcomes in steroid-resistant GVHD better than clinical criteria and should prove useful in developing better treatment strategies. Major-Monfried, H., Renteria, A. S., Pawarode, A., Reddy, P., Ayuk, F., Holler, E., Efebera, Y. A., Hogan, W. J., Wölfl, M., Qayed, M., Hexner, E. O., Wudhikarn, K., Ordemann, R., Young, R., Shah, J., Hartwell, M. J., Chaudhry, M. S., Aziz, M., Etra, A., Yanik, G. A., Kröger, N., Weber, D., Chen, Y.-B., Nakamura, R., Rösler, W., Kitko, C. L., Harris, A. C., Pulsipher, M., Reshef, R., Kowalyk, S., Morales, G., Torres, I., Özbek, U., Ferrara, J. L. M., Levine, J. E. American Society of Hematology (ASH) 0006-4971 00064971 1528-0020 15280020
shingle_title_1	MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD
shingle_title_2	MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD
shingle_title_3	MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD
shingle_title_4	MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD
timestamp	2025-06-30T23:35:42.902Z
titel	MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD
titel_suche	MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD
topic	W WW-YZ
uid	ipn_articles_6289603